Chikungunya vaccine, live (cvx 317) Side Effects
Medically reviewed by Drugs.com. Last updated on Apr 23, 2024.
Applies to chikungunya vaccine, live (cvx 317): intramuscular solution.
Warning
Tell your doctor if you use other medicines or have other medical conditions or allergies.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Chikungunya vaccine may cause low white blood cell counts. This usually occurs within the first week after receiving the vaccine. Tell your doctor if you have fever, mouth sores, skin sores, sore throat or cough. Your white blood cell counts may return to normal within 1 month.
You may have a severe reaction after receiving the vaccine. Call your doctor at once if you have fever, weakness, tiredness, headache, or severe muscle, back or joint pain. These symptoms may prevent you from daily activities, require a hospital stay, or last for weeks or months.
Common side effects may include:
-
pain, redness, swelling, or tenderness where the vaccine was injected;
-
headache, fever, weakness, tiredness; or
-
muscle or joint pain.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to chikungunya vaccine, live (cvx 317): intramuscular solution.
General
The most commonly reported side effects included headache, fatigue, myalgia, and arthralgia.[Ref]
Cardiovascular
Uncommon (0.1% to 1%): Peripheral edema, atrial fibrillation, severe atrial fibrillation
Frequency not reported: Tachycardia[Ref]
Dermatologic
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Hyperhidrosis, erythematous rash
Frequency not reported: Severe rash[Ref]
Gastrointestinal
Very common (10% or more): Nausea (up to 11.2%)
Common (1% to 10%): Vomiting, diarrhea
Frequency not reported: Severe nausea, severe vomiting[Ref]
Hematologic
Very common (10% or more): Grade 1 abnormal neutrophil results (up to 27.6%) grade 1 abnormal leukocyte results (up to 27.3%), grade 1 abnormal lymphocyte results (up to 19.1%), grade 2 abnormal neutrophil results (up to 11.3%)
Common (1% to 10%): Grade 2 abnormal leukocyte results, grade 3 abnormal neutrophil results, grade 2 abnormal lymphocyte results
Uncommon (0.1% to 1%): Grade 3 abnormal leukocyte results, grade 4 abnormal neutrophil results, grade 3 abnormal lymphocyte results, lymphadenopathy[Ref]
Immunologic
Uncommon (0.1% to 1%): Influenza-like illness
Frequency not reported: Chikungunya-like adverse reactions[Ref]
Local
Very common (10% or more): Injection site tenderness (up to 10.6%)
Common (1% to 10%): Injection site pain, injection site erythema/redness (at least 2.5 cm), injection site induration (at least 2.5 cm)
Uncommon (0.1% to 1%): Injection site swelling (at least 2.5 cm)
Rare (0.01% to 0.1%): Severe injection site pain
Frequency not reported: Severe injection site tenderness[Ref]
Metabolic
Frequency not reported: Hypovolemic hyponatremia, increased brain natriuretic peptide[Ref]
Musculoskeletal
Very common (10% or more): Myalgia/muscle pain (up to 23.9%), arthralgia (up to 17.2%)
Common (1% to 10%): Chills, back pain
Uncommon (0.1% to 1%): Severe myalgia/muscle pain, severe arthralgia/joint pain, severe back pain
Frequency not reported: Mild arthralgia, increased troponin, arthritis[Ref]
Nervous system
Very common (10% or more): Headache (up to 31.6%)
Uncommon (0.1% to 1%): Severe headache, dizziness, paresthesia, ataxia, hypoesthesia, peripheral neuropathy, syncope
Frequency not reported: Prolonged arthralgia, polyarthralgia, nodular swelling of joints in fingers and foot[Ref]
Other
Very common (10% or more): Fatigue (up to 28.1%), fever/pyrexia (up to 13.5%)
Common (1% to 10%): Pain
Uncommon (0.1% to 1%): Severe fatigue, severe/worse fever, asthenia, feeling abnormal
Frequency not reported: Prolonged fatigue, severe fever[Ref]
Respiratory
Frequency not reported: Tachypnea[Ref]
More about chikungunya vaccine, live (cvx 317)
- Check interactions
- Compare alternatives
- Dosage information
- Drug class: viral vaccines
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. (2023) "Product Information. Ixchiq (cvx 317) (chikungunya vaccine, live (cvx 317))." Valneva USA
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.